{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T08:02:47Z","timestamp":1793865767938,"version":"4.6.1"},"reference-count":11,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2021,6,20]],"date-time":"2021-06-20T00:00:00Z","timestamp":1624147200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Up to 25% of patients with ulcerative colitis (UC) will require hospitalization for severe flare. In patients hospitalised for severe flare, who previously experienced multiple drug failures, including steroids and anti\u2010TNF agents, new quick\u2010acting medical options are needed. Tofacitinib is effective in refractory UC and has a rapid onset of action.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To evaluate effectiveness and safety of tofacitinib as rescue therapy in patients hospitalised for UC flare.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted an observational and multicentre study with both retrospective and prospective collections in 14 GETAID centres. The primary objective was to assess the survival without colectomy following tofacitinib initiation in patients hospitalised for a UC flare. We determined rates of clinical response, clinical remission, and steroid\u2010free clinical remission at week 6 and week 14 and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fifty\u2010five patients were included (49 with prior infliximab failure and 19 previously exposed to ciclosporin). With a median follow\u2010up of 6.5\u00a0months (interquartile range [IQR] [3\u201012.3]), rate of colectomy\u2010free survival was estimated at 78.9% (95 CI [68.5\u201090.9]) and 73.6% (95 CI [61.9\u201087.3]) at 3 and 6\u00a0months, respectively. Rates of clinical response, clinical remission and steroid\u2010free clinical remission were 60%, 45.5% and 37.5% at week 6 and 41.8%, 34.5% and 32.7% at week 14. Regarding safety, no death was observed, three patients withdrew tofacitinib due to adverse events. Two herpes zoster infections occurred in patients aged over 60\u00a0years old. No venous thrombotic or major adverse cardiovascular events occurred.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Tofacitinib appears as a promising option in patients hospitalised with a UC flare but needs further validation in controlled trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/apt.16463","type":"journal-article","created":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T01:22:57Z","timestamp":1624238577000},"page":"312-319","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Tofacitinib as salvage therapy for 55 patients hospitalised with refractory severe ulcerative colitis: A GETAID cohort"],"prefix":"10.1111","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7761-2879","authenticated-orcid":false,"given":"Mathieu","family":"Uzzan","sequence":"first","affiliation":[{"name":"Clichy France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3506-1519","authenticated-orcid":false,"given":"Cl\u00e9ment","family":"Bresteau","sequence":"additional","affiliation":[{"name":"Kremlin Bicetre France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4753-6676","authenticated-orcid":false,"given":"David","family":"Laharie","sequence":"additional","affiliation":[{"name":"Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4480-9832","authenticated-orcid":false,"given":"Carmen","family":"Stefanescu","sequence":"additional","affiliation":[{"name":"Clichy France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Bellanger","sequence":"additional","affiliation":[{"name":"Kremlin Bicetre France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Carbonnel","sequence":"additional","affiliation":[{"name":"Kremlin Bicetre France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Serrero","sequence":"additional","affiliation":[{"name":"Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Viennot","sequence":"additional","affiliation":[{"name":"Caen France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Nachury","sequence":"additional","affiliation":[{"name":"Lille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lien","family":"Amiot","sequence":"additional","affiliation":[{"name":"Creteil France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Altwegg","sequence":"additional","affiliation":[{"name":"Montpellier France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Picon","sequence":"additional","affiliation":[{"name":"Tours France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Nahon","sequence":"additional","affiliation":[{"name":"Montfermeil France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucine","family":"Vuitton","sequence":"additional","affiliation":[{"name":"Besancon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Ah Soune","sequence":"additional","affiliation":[{"name":"Toulon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Kirchgesner","sequence":"additional","affiliation":[{"name":"Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2536-6618","authenticated-orcid":false,"given":"Laurent","family":"Peyrin\u2010Biroulet","sequence":"additional","affiliation":[{"name":"Vandoeuvre\u2010les\u2010Nancy France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoram","family":"Bouhnik","sequence":"additional","affiliation":[{"name":"Clichy France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"GETAID\u2010TALC Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,6,20]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2010.02.001"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61084-8"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(16)30003-6"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1707500"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2018.11.022"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izaa157"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaa018"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjx008"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/DCR.0000000000001276"},{"key":"e_1_2_9_11_1","unstructured":"Pfizer Shares Co\u2010Primary Endpoint Results from Post\u2010Marketing Required Safety Study of XELJANZ\u00ae(tofacitinib) in Subjects with Rheumatoid Arthritis (RA) | pfpfizeruscom.|Pfizer Shares Co\u2010Primary Endpoint Results from Post\u2010Marketing Required Safety Study of XELJANZ\u00ae (tofacitinib) in Subjects with Rheumatoid Arthritis (RA) | pfpfizeruscom.https:\/\/www.pfizer.com\/news\/press\u2010release\/press\u2010release\u2010detail\/pfizer\u2010shares\u2010co\u2010primary\u2010endpoint\u2010results\u2010post\u2010marketing. Accessed April 21 2021."},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-314015"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.16463","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/apt.16463","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.16463","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T00:38:58Z","timestamp":1693269538000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apt.16463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,20]]},"references-count":11,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["10.1111\/apt.16463"],"URL":"https:\/\/doi.org\/10.1111\/apt.16463","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.740330680.793589726","asserted-by":"object"}]},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,20]]},"assertion":[{"value":"2021-03-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}